Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug 5;154(3):293-304.
doi: 10.1093/ajcp/aqaa112.

Review of Current Advances in Serologic Testing for COVID-19

Affiliations
Comment

Review of Current Advances in Serologic Testing for COVID-19

Andrea P Espejo et al. Am J Clin Pathol. .

Abstract

Objectives: To examine and summarize the current literature on serologic methods for the detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Methods: A literature review was performed using searches in databases including PubMed, medRxiv, and bioRxiv. Thirty-two peer-reviewed papers and 23 preprints were examined.

Results: The studies included lateral flow immunoassay, enzyme-linked immunosorbent assay, chemiluminescence immunoassay, and neutralizing antibody assays. The use of all major SARS-CoV-2 antigens was demonstrated to have diagnostic value. Assays measuring total antibody reactivity had the highest sensitivity. In addition, all the methods provided opportunities to characterize the humoral immune response by isotype. The combined use of IgM and IgG detection resulted in a higher sensitivity than that observed when detecting either isotype alone. Although IgA was rarely studied, it was also demonstrated to be a sensitive marker of infection, and levels correlated with disease severity and neutralizing activity.

Conclusions: The use of serologic testing, in conjunction with reverse transcription polymerase chain reaction testing, was demonstrated to significantly increase the sensitivity of detection of patients infected with SARS-CoV-2. There was conflicting evidence regarding whether antibody titers correlated with clinical severity. However, preliminary investigations indicated some immunoassays may be a surrogate for the prediction of neutralizing antibody titers and the selection of recovered patients for convalescent serum donation.

Keywords: COVID-19; Chemiluminescence immunoassay (CLIA); Convalescent serum; Coronavirus; Enzyme-linked immunosorbent assay (ELISA); Immunoassays; Lateral flow immunoassay (LFIA); Plaque reduction neutralization test (PRNT); SARS-CoV-2; Serology.

PubMed Disclaimer

Comment on

Similar articles

Cited by

References

    1. Chan JF-W, Kok K-H, Zhu Z, et al. . Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9:221-236. doi:10.1080/22221751.2020.1719902. - DOI - PMC - PubMed
    1. WHO. Coronavirus disease 2019 (COVID-19) situation report—134 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio.... Accessed June 2, 2020.
    1. Holshue ML, DeBolt C, Lindquist S, et al. . First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;929-936. doi:10.1056/NEJMoa2001191. - DOI - PMC - PubMed
    1. Lee CY-P, Lin RTP, Renia L, et al. . Serological approaches for COVID-19: epidemiologic perspective on surveillance and control. Front Immunol. 2020. doi:10.3389/fimmu.2020.00879. - DOI - PMC - PubMed
    1. Wölfel R, Corman VM, Guggemos W, et al. . Virological assessment of hospitalized patients with COVID-2019. Nature. 2020. doi:10.1038/s41586-020-2196-x. - DOI - PubMed

Substances